Spinal Muscular Atrophy (Europe)
Established in 2022 by SMA Europe, the Spinal Muscular Atrophy (SMA) PSP will work with people who live with SMA, carers and healthcare professionals to identify uncertainties about spinal muscular atrophy. The scope of the PSP will include treatments, management and care, as well as wellbeing and participation.
SMA is a rare, genetic neuromuscular condition which causes progressive muscle atrophy and weakness, leading to loss of movement.
The image above is of the PSP Steering Group member, Jane Velkovski.